YBYoung Bull
Menu
COMPANY WORKBOOK · DHR

Danaher Corporation

Healthcare & Life Sciences · Diagnostics & Research

$215.84+1.90%
58/100
Overall
MARKET CAP155.42B
FORWARD P/E23.78
PEG RATION/A
REVENUE GROWTH5.5%
OPERATING MARGIN19.8%
52W RANGE$161.57$241.04
ChartScoreRelative StrengthFinancialsThesisFiles
INTERACTIVE PRICE CHART

Trend and moving averages

RELATIVE PERFORMANCE

DHR versus SPY and SMH

Indexed to 100
LIVE MODEL SCORE

Cross-sectional ranking

Momentum60
Technicals67
Fundamentals52
Thematic Fit55

Scores are percentile-ranked against the current Young Bull universe and stored by date in PostgreSQL.

YOUNG BULL THESIS

Healthcare & Life Sciences

This company is available as a market-data workbook. Young Bull has not added a manual investment thesis for it yet.

MODEL READ

Overall score: 58.2. Last ranked 2026-09-22.

QUARTERLY FUNDAMENTALS

Revenue and earnings power

TRAILING P/E39.41
PRICE / SALES6.19
EV / EBITDA22.29
BOOK VALUEN/A
GROSS MARGIN58.8%
PROFIT MARGIN15.9%
RETURN ON EQUITY7.6%
FREE CASH FLOW4.33B
COMPANY SNAPSHOT

What it does

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

PRIMARY SOURCES

Files and filings